Jemon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 01-01-2025
- Paid Up Capital ₹ 0.10 M
as on 01-01-2025
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.70 M
as on 01-01-2025
- Revenue 133.76%
(FY 2022)
- Profit 1616.72%
(FY 2022)
- Ebitda 447.17%
(FY 2022)
- Net Worth 976.95%
(FY 2022)
- Total Assets 63.74%
(FY 2022)
About Jemon Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.70 M.
Bhaveshkumar Patel, Pritesh Shah, and Samirkumar Patel serve as directors at the Company.
- CIN/LLPIN
U24239GJ2020PTC113974
- Company No.
113974
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Jemon Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhaveshkumar Patel  | Director | 15-Jun-2020 | Current |
| Pritesh Shah | Director | 15-Jun-2020 | Current |
| Samirkumar Patel | Director | 15-Jun-2020 | Current |
Financial Performance of Jemon Pharmaceuticals.
Jemon Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 133.76% increase. The company also saw a substantial improvement in profitability, with a 1616.72% increase in profit. The company's net worth Soared by an impressive increase of 976.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jemon Pharmaceuticals?
Unlock access to Jemon Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Jun 2023 | ₹8.70 M | Open |
How Many Employees Work at Jemon Pharmaceuticals?
Jemon Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jemon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jemon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
